December 21, 2020December 21, 2020

Margenza Approved in US for Pretreated HER2-positive Breast Cancer

News

Margenza (margetuximab-cmkb), in combination with chemotherapy, has been approved in the U.S. to treat adults with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 regimens, at ... Read more

February 11, 2019

Margetuximab Helps to Delay Disease Progression in Advanced, HER2-positive Breast Cancers, Phase 3 Trial Shows

News

A combination of MacroGenics‘ HER2 antibody margetuximab and standard chemotherapy is superior to Herceptin (trastuzumab) plus chemotherapy at extending the time to disease progression among advanced and pre-treated breast cancer patients whose tumors ... Read more